Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.34 |
| ▸ | HTR3B | O95264 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.34 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6098149 | 0.90 | CHRNB2 (0.39) | CHRNA7SCN9A | |
| SCHEMBL5917884 | 0.84 | F10 (0.42) | SLC6A4SLC6A3CHRNA7HTR3EHTR3B | |
| SCHEMBL5917825 | 0.84 | ABL1 (0.39) | SLC6A2SLC6A4SLC6A3CHRNA7HTR3E | |
| SCHEMBL5917815 | 0.84 | CHRNA7 (0.48) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6100339 | 0.83 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3CHRNA7SMYD3 | |
| Hydrochloric Acid SCHEMBL5231652 | 0.83 | CHRNA7 (0.47) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6099351 | 0.82 | CHRNA7 (0.37) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6100364 | 0.82 | CHRNA7 (0.33) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6100300 | 0.82 | ABL1 (0.43) | ABL1SCN9A | |
| SCHEMBL6099564 | 0.80 | CHRNA7 (0.34) | SLC6A2SLC6A4SLC6A3CHRNA7HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | SLC6A2 1361/4885SLC6A4 2113/4885SLC6A3 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.